MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
Chemistry World
March 1, 2010
Andy Extance
Bacterial mix sweetens biodrug synthesis Bacteria welcome in the human gut are set to become better factories for biological drugs thanks to modified genes from another, gastroenteritis-causing, species. mark for My Articles similar articles
Chemistry World
June 29, 2015
Organic odysseys Valuable compounds often come from the strangest places, and in such small concentrations that synthetic chemistry has to step up. mark for My Articles similar articles
Chemistry World
July 2008
Ananyo Bhattacharya
Sparks of creation Chemists are at the forefront of synthetic biology, the burgeoning field that could soon create artificial life. mark for My Articles similar articles
Chemistry World
August 27, 2013
Polly Wilson
Hydrogel treatment targets tumors Hydrogels of cancer drug taxol injected directly into tumors have been shown to be more effective at inhibiting tumor growth than intravenous taxol injections of four times the dosage. mark for My Articles similar articles
The Motley Fool
November 18, 2004
Charly Travers
A Glimpse of Bristol-Myers' Portfolio Late-stage drugs are crucial for a company beset with patent losses. mark for My Articles similar articles
Chemistry World
June 30, 2011
Laura Howes
Chemically evolved bacteria European scientists have created an Escherichia coli strain with a separate genome using chlorinated DNA. mark for My Articles similar articles
Wired
August 2003
Jennifer Kahn
The End of Cancer (As we Know it) Diagnosis. Chemotherapy. Radiation. Slow painful death. No more. A new era of cancer treatment is dawning. Meet three scientists who are using the revelations of the Human Genome Project to reshape medicine. mark for My Articles similar articles
Bio-IT World
July 14, 2004
Karen Hopkin
'Omics: The NextGeneration Researchers in industry and academia are cataloging collections of biochemical compounds (metabolomics) to determine how they respond when organisms are challenged by drugs, disease, or stress (metabonomics). mark for My Articles similar articles
The Motley Fool
May 15, 2007
Mike Havrilla
On the Threshold at Sonus The pharma is testing one drug that could be used to treat several types of cancer. Investors, take note. mark for My Articles similar articles
BusinessWeek
April 11, 2005
Arlene Weintraub
Drawing A Bead On Side Effects Drug makers are figuring out ways to make some old remedies such as Propulsid safer. mark for My Articles similar articles
The Motley Fool
September 18, 2006
Brian Lawler
Cell Therapeutics' New Mate The biopharmaceutical company removes some uncertainty by teaming up with Novartis. Investors, take note. mark for My Articles similar articles
Chemistry World
July 1, 2013
James Urquhart
Antibiotic research hits a sweet spot UK researchers have found a way to weaken the molecular armour of Escherichia coli to allow the host's immune system to attack and kill the pathogen. mark for My Articles similar articles
The Motley Fool
January 27, 2005
Wherrett & Yelovich
Billion-Dollar Markets Nanoparticulates offer golden opportunities for investors... if you know where to look. mark for My Articles similar articles
The Motley Fool
January 28, 2011
Brian Orelli
Celgene Needs a Rocket Ship Celgene really needs a hit from Abraxane and other drugs it may license or purchase. mark for My Articles similar articles
BusinessWeek
April 11, 2005
Arlene Weintraub
A Nano Drug's Giant Promise After seeking FDA approval for a decade, American Pharmaceutical Partners' Abraxane, which offers a less-toxic cancer treatment, has doctors and investors hopeful. mark for My Articles similar articles
Bio-IT World
October 2006
Eric K. Neumann
The Advantages of a Drug Safety Commons Once a Drug Safety Commons has been established, a variety of derivative applications will be developed that can access as well as update the information in organized ways and used by industry researchers internally. mark for My Articles similar articles
Chemistry World
September 26, 2006
Fiona Case
Synchronised Delivery for DNA and Drugs Polymer capsules that can simultaneously deliver drug molecules and DNA into a cell could boost the power of cancer treatments. mark for My Articles similar articles
The Motley Fool
April 29, 2004
Bill Mann
Schizophrenia Saves Bristol-Myers Big gains in currencies and schizophrenia drugs help offset some key losses. mark for My Articles similar articles
The Motley Fool
September 25, 2007
Brian Orelli
No Drugs, No Rally Sonus Pharmaceuticals' lead drug fails in phase 3 trials, so the stock crashes. mark for My Articles similar articles
Bio-IT World
July 11, 2002
Kevin Davies
Counting the Cost of Drug Discovery Much of the trouble ensnaring the drug industry is blamed on the exorbitant cost of drug discovery. Tangible proof that the bio-IT revolution will economize drug discovery is emerging, but there is still a long way to go. mark for My Articles similar articles
The Motley Fool
March 30, 2011
Brian Orelli
Amgen's Long Shot Comes Up Short Amgen and Takeda Pharmaceutical's motesanib didn't extend overall survival in lung cancer patients when combined with Bristol-Myers Squibb's Taxol and carboplatin. mark for My Articles similar articles
Chemistry World
June 1, 2012
Philip Ball
A dose by any other name With graphene, fullerenes and dendrimers, scientists have shown that they can sometimes master the trick of balancing euphony, descriptiveness and specificity in chemical naming. mark for My Articles similar articles
The Motley Fool
April 28, 2009
Brian Orelli
Headline? Bad! Unexpected? No! For a company that only has one drug on the market, stopping a failing phase 3 clinical trial that's designed to expand the market of that drug is usually a major blow. But Onyx Pharmaceuticals was able to shrug it off. mark for My Articles similar articles
Chemistry World
October 28, 2008
Hayley Birch
Drug sandwich baits E. coli toxins Polymer scaffolds that pin molecules together at multiple binding sites can trap and destroy E. coli toxins by locking them to immune proteins, researchers based in Canada and Japan have found. mark for My Articles similar articles
The Motley Fool
May 28, 2010
Brian Orelli
This Drug Doesn't Work. But All Is Not Lost. Novartis cancer drug fails one trial, but there's still hope. mark for My Articles similar articles
The Motley Fool
June 15, 2010
Brian Orelli
Just Enough to Give Investors Hope Hitting a secondary endpoint means all is not lost for Onyx's lung cancer drug. mark for My Articles similar articles
BusinessWeek
June 16, 2011
Langreth & Cortez
When Two Cancer Drugs Are Better Than One Drugmakers are collaborating to test combinations of genetically targeted cancer drugs in hopes of boosting survival rates. mark for My Articles similar articles
The Motley Fool
March 30, 2010
Brian Orelli
Invest in This Space at Your Own Risk Lung cancer is a tough foe for drugmakers. mark for My Articles similar articles
The Motley Fool
April 8, 2008
Brian Orelli
Songs of the One-Drug Wonders Will these companies become big-name drugmakers or get lost in history? Let's take a quick look at: Abraxis Bioscience... Elan... Amylin Pharmaceuticals... Onyx Pharmaceuticals... mark for My Articles similar articles
The Motley Fool
November 11, 2010
Brian Orelli
ATTRACTing Clinical Trial Failure Let's not make it a habit, Novartis. Novartis is dropping development of lung-cancer treatment ASA404 after a second failed phase 3 trial. mark for My Articles similar articles
PC Magazine
August 8, 2008
Carol L. Gonsher
Storing Data on Living Computers DNA stores an awful lot of information, so why not computer data? mark for My Articles similar articles
Chemistry World
February 19, 2009
Nina Notman
Nanoparticles give cancer drug a boost US scientists have taken a novel step towards fighting the reoccurrence of lung cancer, using drug delivering nanoparticles. mark for My Articles similar articles
Chemistry World
June 24, 2014
Elisabeth Ratcliffe
Human protein cleans drinking water Researchers in Japan have shown that they can remove Escherichia coli from drinking water using tiny tubes made of human serum albumin. mark for My Articles similar articles
The Motley Fool
July 28, 2006
Jack Uldrich
Tiny Particles Cause a Big Storm for Abraxis Elan sues Abraxis Bioscience for patent infringement. Abraxis' stock, which has fallen nearly 60% from its 52-week high, might make a compelling buy for more risk-tolerant investors. mark for My Articles similar articles
Chemistry World
March 5, 2012
Harriet Brewerton
Picturing Bacteria on Your Phone US scientists have developed a device that, when attached to a mobile phone, can detect small amounts of Escherichia coli in liquid samples. mark for My Articles similar articles
The Motley Fool
January 25, 2006
Stephen D. Simpson
Bristol-Myers Catches a Cold Tough days are coming, but so are promising new drugs. It's understandable why long-term investors might be willing to hold on and see how things work out. mark for My Articles similar articles
BusinessWeek
February 16, 2004
Catherine Arnst
Medicare vs. Cancer Patients Refusing to reimburse off-label treatment is far from the best way to cut costs. mark for My Articles similar articles